Market capitalization | $41.28m |
Enterprise Value | $-39.36m |
P/E (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | -5.32 |
P/S ratio (TTM) P/S ratio | 5.58 |
P/B ratio (TTM) P/B ratio | 0.96 |
Revenue growth (TTM) Revenue growth | -69.51% |
Revenue (TTM) Revenue | $7.40m |
EBIT (operating result TTM) EBIT | $-27.48m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
2 Analysts have issued a LAVA Therapeutics NV forecast:
2 Analysts have issued a LAVA Therapeutics NV forecast:
Jun '24 |
+/-
%
|
||
Revenue | 7.40 7.40 |
69%
69%
|
|
Gross Profit | 7.23 7.23 |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -27 -27 |
32%
32%
|
Net Profit | -24 -24 |
41%
41%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The firm develops next generation T-cell engaging bispecific antibodies to treat cancer. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.
Head office | Netherlands |
CEO | Stephen Hurly |
Employees | 37 |
Founded | 2016 |
Website | www.lavatherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.